The G-HiFi™ DNA Polymerase is a new genetically modified, recombinant DNA polymerase suitable for GC-rich templates that are difficult to amplify. The fidelity of G-HiFi™ DNA Polymerase is 70 times higher than that of Taq DNA polymerase. The high extension rate of G-HiFi™ DNA Polymerase is achieved by blending the DNA polymerase with an elongation enhancer. The optimized 5X G-HiFi™ Buffer includes special ingredients that suppress non-specific amplification as well as plateau effect produced by conventional PCR. With the optimized 5X G-HiFi™ Buffer, G-HiFi™ DNA Polymerase is capable to amplify most templates, such as longer targets (up to 40 kb from lambda DNA) and that contain GC-rich sequences.
Detail
Description
The G-HiFi™ DNA Polymerase is a new genetically modified, recombinant DNA polymerase suitable for GC-rich templates that are difficult to amplify. The fidelity of G-HiFi™ DNA Polymerase is 70 times higher than that of Taq DNA polymerase. The high extension rate of G-HiFi™ DNA Polymerase is achieved by blending the DNA polymerase with an elongation enhancer. The optimized 5X G-HiFi™ Buffer includes special ingredients that suppress non-specific amplification as well as plateau effect produced by conventional PCR. With the optimized 5X G-HiFi™ Buffer, G-HiFi™ DNA Polymerase is capable to amplify most templates, such as longer targets (up to 40 kb from lambda DNA) and that contain GC-rich sequences.
Features
5’→3’ DNA polymerase activity
3’→5’ exonuclease (proofreading) activity
Suitable for GC-rich templates
High reaction rate: 7 seconds/kb
High fidelity: 70 times higher than Taq polymerase
Generates blunt end amplicons
Vast elongation capability (up to 40 kb)
Thermo-stable for more than 10 hrs at 95°C
Storage
[TF3000] G-HiFi™ DNA Polymerase
-20°C for 24 months
Other Products
Hepatitis C Virus (HCV) TaqMan RT-PCR Detection Kits
Product Info
Document
Product Info
Overview
Detection kits for HCV
Available in TaqMan format for analysis
Hepatitis C virus infection is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) worldwide. Neither a vaccine nor an effective treatment is available for HCV. Pegylated interferon-α (PEG-IFN- α), combined with ribavirin, is the current standard therapy. Its efficiency ranges between 20-80%, depending on the HCV genotype. Unfortunately, many HCV infected patients do not respond to or do not tolerate the IFN-based therapy. Therefore, the number of patients progressing to HCC, as a result of HCV infection, is expected to increase over the next 20-30 years. The natural history of the disease reveals the elusive nature of the virus in a number of features. First, the infection is often detected incidentally at the time of blood donation as the acute infection is clinically asymptomatic in most patients. Second, HCV successfully escapes multi-specific host immune responses in the majority of patients which establishes persistent infection. Third, a significant number of persistently infected individuals remain unaware of the infection for decades, until liver fibrosis, cirrhosis and/or hepatocellular carcinoma develop.
HCV TaqMan RT-PCR Kit, 100 reactions
Ready to use format, including Master Mix for the target and PCR control to monitor for PCR inhibition and validate the quality
Specific Primer and Probe mix for the pathogen/virus/viroid of interest
Primer and Probe mix
Positive and negative control to confirm the integrity of the kit reagents
HCV TaqMan RT-PCR Probe/Primer Set and Controls, 100 reactions
Specific Primer/Probe mix and Positive Control for the pathogen/virus/viroid of interest
Nuclease-free water
Can be used together with Norgen’s RT-PCR Master Mix (#28113) or customer supplied master mix
For research use only and NOT intended for in vitro diagnostics.
Storage Conditions and Product Stability All kit components can be stored for 1 year after the date of production without showing any reduction in performance.
All kit components should be stored at -20°C upon arrival.
